根治性前列腺切除术后前列腺特异性抗原检测能否在20年时停止
研究纳入16,720例根治性前列腺切除术患者,其中2,699例出现生化复发。在732例术后20年无复发且PSA检测不到的患者中,仅17例(2.3%)出现生化复发、1例发生转移、无前列腺癌死亡。作者认为20年是停止PSA检测的合理时间。
要点
- 延迟生化复发者转移和前列腺癌死亡累积发生率优于早期复发者。
- 术后20年PSA检测不到的732例中,生化复发17例(2.3%),转移1例,无死亡。
- 作者认为20年是停止PSA检测的合理时间。
核心结论
- 延迟生化复发患者临床特征良好且生存改善。
- 术后20年PSA检测不到者复发率低且无前列腺癌死亡,提示20年是停止PSA检测的合理时间。
研究设计与样本
- 回顾性分析16,720例根治性前列腺切除术患者,其中2,699例出现生化复发;对732例术后20年及以上无复发随访者进行亚组分析。
主要发现
- 延迟生化复发的预测因素包括根治性前列腺切除术时PSA升高、更高的临床和病理分期及手术切缘阳性。
- 延迟生化复发者转移和前列腺癌死亡的累积发生率曲线优于早期生化复发者。
- 732例术后20年PSA检测不到者中,17例(2.3%)出现生化复发,1例发生转移,无前列腺癌死亡。
- 术后20年PSA检测不到者中,生化复发的Actuarial概率随不良病理特征增加而升高。
临床怎么用
- 作者认为术后20年PSA检测不到者可在20年时停止PSA检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We examined the clinical features and outcomes associated with delayed biochemical recurrence after radical prostatectomy, specifically among men with more than 20 years of followup. MATERIALS AND METHODS: A total of 16,720 men underwent radical prostatectomy and 2,699 experienced biochemical recurrence. We determined predictors of delayed biochemical recurrence as well as metastasis-free and cancer specific survival rates for recurrence at various time points after radical prostatectomy. We performed subset analysis of the 732 men with 20 or more years of recurrence-free followup. Cumulative incidence curves for metastasis and prostate cancer death were calculated and stratified by biochemical recurrence time points. RESULTS: Predictors of delayed biochemical recurrence included elevated prostate specific antigen at radical prostatectomy, higher clinical and pathological stage, and positive surgical margins. Delayed biochemical recurrence was associated with favorable cumulative incidence curves for metastasis and prostate cancer death compared to early biochemical recurrence. Among the 732 men with undetectable prostate specific antigen at 20 years biochemical recurrence developed in 17 (2.3%), metastatic disease developed in a single patient and none died of prostate cancer. The actuarial probability of biochemical recurrence among men with undetectable prostate specific antigen at 20 years increased with adverse pathological features. CONCLUSIONS: Men with delayed biochemical recurrence have favorable clinical features and improved survival. Men with undetectable prostate specific antigen 20 years after radical prostatectomy had a low rate of recurrence and no deaths from prostate cancer. This suggests that 20 years is a reasonable time to discontinue prostate specific antigen testing.
引用
- Ludwig WW, Feng Z, Trock BJ, et al. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years? J Urol. 2017. PMID: 28818527. doi:10.1016/j.juro.2017.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。